Every earnings call for ANTHEM — management tone, guidance, KPIs and promise tracking, quarter by quarter.
ANTHEM · 5 transcripts · Healthcare · latest Q1 FY27Anthem Biosciences Limited has 5 earnings calls on record here, a Healthcare company, most recently Q1 FY27. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue ₹418 cr; EBITDA ₹176 cr; EBITDA Margin 39.6%. Consolidated revenues from operations for Q1 FY27 were Rs. 418 crores.
Read full transcript & analysisTotal Revenue (FY26) ₹2,280 cr (+18% YoY); EBITDA (FY26) ₹990 cr (+31% YoY); EBITDA Margin (FY26) 43.4%. Consolidated revenue for FY26 reached ₹2,280 crores, an 18% YoY growth.
Read full transcript & analysisRevenue (9M FY26) ₹1,513 cr (+11% YoY); EBITDA (9M FY26) ₹671 cr (+23% YoY); EBITDA Margin (9M FY26) 41.5%. 9M FY26 consolidated revenue from operations at ₹1,513 crore.
Read full transcript & analysisConsolidated Revenue ₹1,090 cr; EBITDA ₹480 cr; EBITDA Margin 41.4%. H1 FY26 consolidated revenue from operations reached ₹1,090 crores.
Read full transcript & analysisConsolidated Revenue ₹540 cr; EBITDA ₹214 cr; EBITDA Margin 38%. Consolidated revenue of INR 540 crores.
Read full transcript & analysis